DSRU Scientific Publications
Use our keyword search facility to match our publications with your area of interest.
253 publications found, showing 61 to 80
-
Prescription-Event Monitoring (PEM) Study of Sildenafil in England.
Boshier A, Shakir SAW,
Am J Urol Review. January 2004 -
Yellow Card and 'green form' reporting: when is it necessary?
Layton D, Shakir SAW,
Supplementary Prescribing in Practice. January 2004 -
Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000
Boshier A, Wilton LV, Shakir SA,
Eur J Clin Pharmacol. December 2003 -
Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data
Layton D, Hughes K, Harris S, Shakir SA,
Rheumatology (Oxford). November 2003 -
Pharmacovigilance study of alendronate in England
Biswas PN, Wilton LV, Shakir SA,
Osteoporos Int. July 2003 -
Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data
Layton D, Heeley E, Hughes K, Shakir SA,
Rheumatology (Oxford). May 2003 -
The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England
Biswas PN, Wilton LV, Shakir SA,
J Psychopharmacol. March 2003 -
Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study
Layton D, Riley J, Wilton LV, Shakir SA,
Br J Clin Pharmacol. February 2003 -
Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England
Craig-McFeely PM, Wilton LV, Soriano JB, Maier WC, Shakir SA,
Int J Clin Pharmacol Ther. February 2003 -
Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data
Layton D, Heeley E, Hughes K, Shakir SA,
Rheumatology (Oxford). January 2003 -
Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England
Wilton L, Kollarova M, Heeley E, Shakir S,
Drug Saf. January 2003 -
Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future
Layton D, Key C, Shakir SA,
Pharmacoepidemiol Drug Saf. January 2003 -
The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England
Wilton LV, Key C, Shakir SA,
Drug Saf. January 2003 -
Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK
Layton D, Sinclair HK, Bond CM, Hannaford PC, Shakir SA,
Pharmacoepidemiol Drug Saf. September 2002 -
A case of nonarteritic ischemic optic neuropathy (NAION) in a male patient taking sildenafil
Boshier A, Pambakian N, Shakir SA,
Int J Clin Pharmacol Ther. September 2002 -
A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England
Wilton LV, Shakir S,
Epilepsia. September 2002 -
A post-marketing observational study to assess the safety of mibefradil in the community in England
Riley J, Wilton LV, Shakir SA,
Int J Clin Pharmacol Ther. June 2002 -
Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety
Key C, Layton D, Shakir SAW,
Pharmacoepidemiol Drug Saf. March 2002 -
Monitoring safety of over the counter drugs [3] (multiple letters)
Wade AG, Walmsley J, Marshall G, Layton D, Shakir SAW, Clark D,
BMJ. February 2002 -
Automated signal generation in prescription-event monitoring
Heeley E, Wilton LV, Shakir SA,
Drug Saf. January 2002